

**Source:** Diagnamed Holdings Corp.

April 11, 2023 07:30 ET

## DiagnaMed Announces Listing on OTCQB in the United States

TORONTO, April 11, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a digital health AI company, is pleased to announce that effective April 11, 2023, the Company is listed on the OTCQB Venture Market ("OTCQB") under the symbol "DGNMF". The Company will continue to trade on the Canadian Securities Exchange ("CSE") under its existing symbol "DMED".

The Company has also applied to the Depository Trust Company ("DTC") for DTC eligibility, which would greatly simplify the process of trading the Company's common shares. The Company expects to receive DTC eligibility approval shortly.

The OTCQB, which is a U.S. trading platform operated by OTC Markets Group Inc., offers investors transparent trading in entrepreneurial and development stage companies. The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities. To be eligible, companies must be current in their reporting and must undergo an annual verification and management certification process. Becoming an OTCQB-listed issuer introduces additional international compliance and disclosure standards for DiagnaMed. The potential benefits of trading on the OTCQB include efficient market standards, as well as increased transparency, liquidity and visibility within the U.S. investment community.

Investors or other interested parties in the U.S. can obtain real-time quotes for DiagnaMed, as well as access the Company's most current news and information at [www.otcm Markets.com](http://www.otcm Markets.com).

### About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF), a digital health AI company, is focused on the development and commercialization of CERVAI™, a proprietary Brain Health AI Platform for mental health and neurodegenerative disorders. Learn more at [DiagnaMed.com](http://DiagnaMed.com).

For more information about DiagnaMed, please contact:

Fabio Chianelli  
Chairman of the Board  
DiagnaMed Holdings Corp.  
Tel: 416-800-2684  
Email: [info@diagnamed.com](mailto:info@diagnamed.com)  
Website: [www.diagnamed.com](http://www.diagnamed.com)

*Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.*

### Cautionary Statement

*Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "may", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital*

*market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in DiagnaMed's final prospectus dated October 26, 2022, which is available on the Company's profile at [www.sedar.com](http://www.sedar.com). Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

*This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.*